By Kim Bellard
Amid the entire drama last week with rates, commercial wars and currency of market legislation, it is possible that the National Security Commission on Emerging Biotechnology (NSCEB) issued its report: Trace the future of biotechnology. In fact, it is possible that it has been lost when Congress created the commission in 2022; I know I did.
Biotechnology is a big problem and will make much bigger. John Cumbers, founder and CEO of Synbiobeta, writes that US bioecomy is already worth $ 950 billion, and quotes the McKinsey Global Institute as a predicted that by 2040, biology could generate 30% of the world’s physical opportunity. It is not an opportunity that the United States can afford to be lost, however, that is exactly what may be happening.
The NSCEB report establishes bets:
We stand on the edge of a new industrial revolution, one that depends on our ability to design biology. Emerging biotechnology, together with artificial intelligence, will transform everything from the way we defend and build our nation to how we feed and provide attention to Americans.
Unfortunately, the report continues: “We now believe that the United States is staying behind in key areas of emerging biotechnology as China advances.”
Its main conclusion: “China quickly amounts to the mastery of biotechnology, after having made biotechnology a strategic priority for 20 years.1 To remain competitive, the United States must take quick measures in the next three years. Otherwise, we risk being left behind, a setback from which we may never recover. “
The senator of the president of NSCEB, Todd Young, elaborated:
The United States is locked in a competition with China that will define the next century. Biotechnology is the following phase in that competition. It is no longer built for the kingdom of scientific achievement. Now it is an imperative for national security, economic power and global influence. Biotechnology can ensure that our warriors continue to be the strongest struggle force in the Battle fields of tomorrow and resort the supply chains while revitalizing our manufacturing sector, creating jobs here at home.
“We are about to see that decades of progress occur, apparently, during the night … touching almost all aspects of our lives: agriculture, industry, energy, defense and national security,” said Michelle Rozo, PHD, Molecular Biologist and Vice President of NSCeB, while testifying before the subcommittee of the Armed Services Committee of April 8 in Cyber, Information Technology and Innovation. However, she continued, “the strengths of the biotechnology of the United States are atrophy, dangerous.”
Paul Zhang, partner of Bluestar Bioadvisors, who advises drug manufacturers on commercial strategies, including business search in China, explained to The Wall Street Journal How China’s manufacturing objectives have evolved: “Initially, it was how to make faster, cheaper and better shoes and sneakers.
If you think NSCEB is being alarmist, Julie HENG, writing for the Center for Strategic and International Studies (CSI), notes:
During the last decade, China has dramatically increased its investments in biotechnology, with the R&D of biopharma that grows 400 times and the market value of biotechnological companies that increase 100 times between 2016 and 2021, now it reaches a collective or $ 300 billion … depend on Chinese contractual companies for manufacturing. In addition, China continues an effort from the entire government to support its national industry with fines, regulatory rationalization and diplomatic support, builds more than 100 biotechnological research parks and 17 industrial groups.
It is worse than being out of manufactured. The Commission “You have Every Reason to Believe That the CCP Will Weaponize Biotechnology,” and describes Sub Scary Scenarios, Including Genetically Enhanced “Super Soldiers,” Using Microbes to Degrade Wood and Deprading Pathling and Infasting Izdings and Infrastructure and Infrastructure and Infrastructure and Infrastructure and Infrastructure infrastructure ergdens ergendings ergendings and infrastructure ergdens ergendings ergendings Ergendings Ergdens Ergendings e infraestructura ergdens ergendings ergdens ergendings ergendings e infraestructura, ergdens ergd estructura ergdens ergendings ergendings ergendings ERGENDINS ERGENDINS ERGIFERS EGGENDRES ERGENDINGS EGGENDINGS ERGENDINGS ERGENDINGS ERGENDINGS EGGENDINGS ERGENDINGS ERGENDINS ZAR ERGENDINS ERGDENS ERGDENS. Cultivated in the USA. If that doesn’t scare you, I don’t know what it does.
Therefore, the commission says: “If the United States does not act, the future of biotechnology could be catastrophic.”
The commission suggests a plan. The report presents six “pillars” and 49 recommendations. The six pillars are:
- Pilar 1: Prioritize biotechnology at the national level
- Pilar 2: Mobilize the private sector so that the products make us
- Pilar 3: Maximize the benefits of biotechnology for defense
- Pilar 4: Innovate our strategic competitors
- Pilar 5: Build the biotechnology workforce of the future
- Pilar 6: Mobilize the collective strengths of our allies and partners
The objective of the commission is not “outside China China”, but “to rely on our inherent strengths.” Its key recommendation is to invest a minimum of $ 15B in the next five years, hoping to attract even more private capital to the field. It also requires a National Office for Biotechnology Coordination to help boost government strategy.
With everything that is at stake, $ 15b seems enough. Hopefully Dooge does not discover it.
I should notice that David Wainer, writing in WSJHe points out: “The US biotechnology sector had already gone through a brut before the last in the last.
Dr. Cumbers Insta:
We have the peace calls and the Bible Belt – Noow, we build a Bio belt: a national network of regional bioman -abuse centers. These centers would boost innovation: they would boost economic renewal, especially in rural and industrial regions. While some works will go to scientists and engineers, many more will go to merchants, factor workers and high school graduates trained to run and maintain next generation biofacilities.
And he warns: “If we fail to develop the ability to do what we invent, we will see the returns of American innovation.” We have that movie too many times, in other sectors, and it doesn’t end well for us.
We definitely need to make biotechnology a priority. The Federal National Investment and Coordination Office seems to be solid recommendations. The problem is that we need the same in AI and Robotics, just to name two other key emerging industries. The current administration focuses so much on bringing 20Th The industries of the century, such as coal mining and car manufacturing, have to ask myself: who is looking towards the future, not behind?
Kim is a former emarketing executive in an important blues plan, editor of The Late & larmente Tintura.ioAnd now regular THCB collaborator